Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

NCT03333486 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

OTHER

Sponsor class

Stopped Futility analysis determined closure

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Leukemia in Remission
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia With FLT3/ITD Mutation
Acute Myeloid Leukemia With Gene Mutations
Aplastic Anemia
B-Cell Non-Hodgkin Lymphoma
CD40 Ligand Deficiency
Chronic Granulomatous Disease
Chronic Leukemia in Remission
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Myelomonocytic Leukemia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Congenital Amegakaryocytic Thrombocytopenia
Congenital Neutropenia
Congenital Pure Red Cell Aplasia
Glanzmann Thrombasthenia
Immunodeficiency Syndrome
Myelodysplastic Syndrome
Myelofibrosis
Myeloproliferative Neoplasm
Paroxysmal Nocturnal Hemoglobinuria
Plasma Cell Myeloma
Polycythemia Vera
Recurrent Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Secondary Acute Myeloid Leukemia
Secondary Myelodysplastic Syndrome
Severe Aplastic Anemia
Shwachman-Diamond Syndrome
Sickle Cell Disease
T-Cell Non-Hodgkin Lymphoma
Thalassemia
Waldenstrom Macroglobulinemia
Wiskott-Aldrich Syndrome

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine Phosphate
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Peripheral Blood Stem Cell Transplantation
RADIATION: Total-Body Irradiation

Sponsor

Roswell Park Cancer Institute